Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results103

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results22

Views

Views
December 20252
January 20261
February 20261
March 20263
April 20260
May 20266
June 20269
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
United Kingdom4
Netherlands3
Venezuela2
Argentina2
Bolivia1
Chile1
Colombia1
Ecuador1
Spain1
 

Top cities views

Views
Amsterdam3
Birmingham1
Buenos Aires1
Chicago1
Fes1
Ituzaingó1
Kintore1
La Guaira1
Maracaibo1
Port Saint Lucie1